Titre de série :	Topics in Current Chemistry
Titre :	Vol.299 : Chemistry of opioids
Type de document :	texte imprimé
Auteurs :	H. Nagase, Éditeur scientifique
Editeur :	Berlin, Heidelberg : Springer
Année de publication :	2011
Collection :	Topics in Current Chemistry, ISSN 0340-1022 num. 299
Importance :	312 p.
Présentation :	ill.
Format :	24 cm
ISBN/ISSN/EAN :	978-3-642-18106-1
Langues :	Anglais (eng)
Note de contenu :	"* Recent advances in the synthesis of morphine and related alkaloids * Opioids in preclinical and clinical trials * Synthesis of 14-alkoxymorphinan derivatives and their pharmacological actions * 14-amino-4,5-epoxymorphinan derivatives and their pharmacological actions * Nonpeptidic delta (?) opioid agonists and antagonists of the diarylmethylpiperazine class: what have we learned * Synthesis of neoclerodane diterpenes and their pharmacological effects * Synthesis of novel basic skeletons derived from naltrexone * Twin and triplet drugs in opioid research * 3D-Pharmacophore identification for ?-opioid agonists using ligand-based drug-design techniques."
Cote :	EXCLU (SdL)
Num_Inv :	3037

Topics in Current Chemistry. Vol.299 : Chemistry of opioids [texte imprimé] / H. Nagase, Éditeur scientifique . - Berlin, Heidelberg : Springer, 2011 . - 312 p. : ill. ; 24 cm. - (Topics in Current Chemistry, ISSN 0340-1022; 299) .
ISBN : 978-3-642-18106-1
Langues : Anglais (eng)

Note de contenu :	"* Recent advances in the synthesis of morphine and related alkaloids * Opioids in preclinical and clinical trials * Synthesis of 14-alkoxymorphinan derivatives and their pharmacological actions * 14-amino-4,5-epoxymorphinan derivatives and their pharmacological actions * Nonpeptidic delta (?) opioid agonists and antagonists of the diarylmethylpiperazine class: what have we learned * Synthesis of neoclerodane diterpenes and their pharmacological effects * Synthesis of novel basic skeletons derived from naltrexone * Twin and triplet drugs in opioid research * 3D-Pharmacophore identification for ?-opioid agonists using ligand-based drug-design techniques."
Cote :	EXCLU (SdL)
Num_Inv :	3037